{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:09Z","timestamp":1793213409301,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Supportive care interventions used to manage chemotherapy\u2010induced myelosuppression (CIM), including granulocyte colony\u2010stimulating factors (G\u2010CSFs), erythropoiesis\u2010stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to patients and associated with greater costs to health care systems. We evaluated the utilization of supportive care interventions and their relationship with the myeloprotective agent, trilaciclib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were pooled from three independent randomized phase 2 clinical trials of trilaciclib or placebo administered prior to chemotherapy in patients with extensive\u2010stage small cell lung cancer (ES\u2010SCLC). The impact of supportive care on the duration of severe neutropenia (DSN), occurrence of severe neutropenia (SN), and occurrence of RBC transfusions on\/after week 5 was analyzed across cycles 1\u20134. Concordance and association between grade 3\/4 anemia, RBC transfusions on\/after week 5, and ESA administration was also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The use of G\u2010CSFs, ESAs, or RBC transfusions on\/after week 5 was significantly lower among patients receiving trilaciclib versus placebo (28.5% vs. 56.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.0001; 3.3% vs. 11.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.0254; and 14.6% vs. 26.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.0252, respectively). Compared with placebo, trilaciclib significantly reduced DSN and SN, irrespective of G\u2010CSF administration. RBC transfusions and ESAs were most often administered in patients with grade 3\/4 anemia; however, patients typically received RBC transfusions over ESA administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By improving CIM and reducing the need for associated supportive care, trilaciclib has the potential to reduce the burden of myelosuppression on patients receiving myelosuppressive chemotherapy for the treatment of ES\u2010SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (NCT02499770; NCT03041311; NCT02514447).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.4089","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T04:37:23Z","timestamp":1629261443000},"page":"5748-5756","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy\u2010induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-215X","authenticated-orcid":false,"given":"Renata","family":"Ferrarotto","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Anderson","sequence":"additional","affiliation":[{"name":"St Joseph Heritage Healthcare Santa Rosa CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Medgyasszay","sequence":"additional","affiliation":[{"name":"Veszpr\u00e9m County Lung Medicine Institute Veszpr\u00e9m Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosario","family":"Garc\u00eda\u2010Campelo","sequence":"additional","affiliation":[{"name":"University Hospital A Coru\u00f1a A Coru\u00f1a Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Edenfield","sequence":"additional","affiliation":[{"name":"Prisma Health Cancer Institute Greenville SC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor M.","family":"Feinstein","sequence":"additional","affiliation":[{"name":"Piedmont Cancer Institute Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University Hospital Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Kalmadi","sequence":"additional","affiliation":[{"name":"Ironwood Cancer &amp; Research Center Chandler AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E.","family":"Lammers","sequence":"additional","affiliation":[{"name":"Baptist Cancer Center Memphis TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Sanchez\u2010Hernandez","sequence":"additional","affiliation":[{"name":"Hospital Provincial de Castellon Castell\u00f3 Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Pritchett","sequence":"additional","affiliation":[{"name":"G1 Therapeutics, Inc. Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon R.","family":"Morris","sequence":"additional","affiliation":[{"name":"G1 Therapeutics, Inc. Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh K.","family":"Malik","sequence":"additional","affiliation":[{"name":"G1 Therapeutics, Inc. Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Cs\u0151szi","sequence":"additional","affiliation":[{"name":"Hetenyi Geza Korhaz Szolnok Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.5392"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219622"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01419-6"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04875-1"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.10.006"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2019.07.03"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2012.03.001"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014534515"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02142"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0775"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3986"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14664"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz278"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33453"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01538-0"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.03.010"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5354-5"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0002"},{"key":"e_1_2_13_24_1","first-page":"1","article-title":"Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID\u201019 pandemic","author":"Griffiths EA","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1140052"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJCTM.S187569"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102837"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200727060-00002"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19300"},{"key":"e_1_2_13_30_1","first-page":"173","article-title":"Economic burden related to chemotherapy\u2010related adverse events in patients with metastatic breast cancer in an integrated health care system","volume":"8","author":"Rashid N","year":"2016","journal-title":"Breast Cancer (Dove Med Press)"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4089","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4089","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T13:09:12Z","timestamp":1693314552000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1002\/cam4.4089"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4089","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"2021-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}